Menopause Practice Questions

Q: Which of the following is NOT a long-term benefit of hormone replacement therapy?

Increased duration of menstrual cycles. **Explanation:** The correct answer is **C. Increased duration of menstrual cycles.** **1. Why Option C is correct:** Menopause is physiologically defined by the permanent cessation of menstruation due to the loss of ovarian follicular activity. Hormone Replacement Therapy (HRT) is administered to alleviate vasomotor symptoms and prevent long-term complications of estrogen deficiency. While HRT (specifically cyclical progesterone) may cause "withdrawal bleeding," it does not restore or increase the duration of the natural menstrual cycle. Furthermore, the goal of HRT in postmenopausal women is symptom management, not the restoration of fertility or the menstrual cycle. **2. Why the other options are incorrect:** * **Option A (Colorectal Cancer):** Large-scale studies, including the Women’s Health Initiative (WHI), demonstrated that combined HRT (Estrogen + Progesterone) is associated with a **reduced risk** of colorectal cancer. * **Option B & D (Fractures and BMD):** Estrogen inhibits osteoclast activity. HRT is highly effective in **increasing Bone Mineral Density (BMD)** and significantly **reducing the risk of osteoporotic fractures** (hip and vertebral). This is considered one of its primary long-term benefits. **3. NEET-PG High-Yield Pearls:** * **Indications:** The primary indication for HRT is moderate-to-severe vasomotor symptoms (hot flashes). * **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60. * **Risks:** Combined HRT increases the risk of breast cancer (after 3-5 years of use), stroke, and Venous Thromboembolism (VTE). * **Uterus Rule:** If the uterus is intact, **never** give estrogen alone (unopposed estrogen) due to the high risk of endometrial hyperplasia and carcinoma; always add progesterone.

Q: Postmenopausal hormone replacement therapy decreases the incidence of which malignancy?

Colorectal. **Explanation:** The correct answer is **Colorectal cancer**. Large-scale clinical trials, most notably the **Women’s Health Initiative (WHI)**, have demonstrated that combined Hormone Replacement Therapy (HRT) with estrogen and progestin is associated with a **significant reduction (approximately 30-40%)** in the risk of colorectal cancer. The underlying mechanism is believed to involve estrogen’s ability to decrease the production of secondary bile acids (which are carcinogenic to the colonic mucosa) and its direct inhibitory effect on the growth of colonic epithelial cells via estrogen receptors (ER-β) in the gut. **Analysis of Incorrect Options:** * **A. Breast Cancer:** Long-term use of combined HRT (Estrogen + Progestin) is a well-known risk factor for breast cancer. Estrogen-only therapy has a lower risk but is not protective. * **C. Ovarian Cancer:** Most epidemiological studies suggest that long-term HRT use slightly **increases** the risk of ovarian cancer (particularly serous and endometrioid types). * **D. Endometrial Cancer:** Unopposed estrogen therapy in women with an intact uterus significantly increases the risk of endometrial hyperplasia and carcinoma. While adding progestin mitigates this risk, HRT does not decrease the baseline incidence. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Indication for HRT:** Moderate to severe vasomotor symptoms (hot flashes, night sweats). * **Bone Health:** HRT is highly effective in preventing **osteoporotic fractures**, but it is generally not the first-line treatment for osteoporosis alone due to other risks. * **Cardiovascular Risk:** HRT increases the risk of **Venous Thromboembolism (VTE)**, stroke, and coronary heart disease (if started late in menopause). * **The "Window of Opportunity" Hypothesis:** HRT is safest and most beneficial when started in women under 60 years of age or within 10 years of menopause onset.

Q: Hormone therapy in postmenopausal women is indicated for treatment of all the following conditions EXCEPT:

Cardiovascular disease. **Explanation:** The correct answer is **Cardiovascular disease (D)**. While estrogen was historically thought to be cardioprotective, major clinical trials like the **Women’s Health Initiative (WHI)** demonstrated that Hormone Replacement Therapy (HRT) does not prevent primary or secondary cardiovascular events. In fact, initiating HRT in older postmenopausal women may increase the risk of stroke and thromboembolism. Therefore, HRT is strictly **contraindicated** for the sole purpose of cardiovascular protection. **Analysis of other options:** * **Vasomotor symptoms (A):** This is the **most common indication** for HRT. Estrogen effectively treats "hot flashes" and night sweats by stabilizing the thermoregulatory center in the hypothalamus. * **Osteoporosis (B):** Estrogen inhibits osteoclast activity. HRT is FDA-approved for the prevention of postmenopausal osteoporosis, particularly in women at high risk of fractures who cannot tolerate other therapies. * **Vaginal atrophy (C):** Also known as Genitourinary Syndrome of Menopause (GSM), estrogen restores vaginal pH and moisture. For isolated vaginal symptoms, local (topical) estrogen is preferred over systemic therapy. **High-Yield NEET-PG Pearls:** 1. **The "Window of Opportunity" Hypothesis:** HRT is safest and most effective when started within 10 years of menopause or before age 60. 2. **Progesterone Addition:** In women with an **intact uterus**, progesterone must be added to estrogen to prevent endometrial hyperplasia and carcinoma. 3. **Contraindications:** Undiagnosed abnormal uterine bleeding, active liver disease, history of breast cancer, and active thromboembolism (DVT/PE). 4. **Drug of choice for premature ovarian insufficiency:** HRT is mandatory until the natural age of menopause (approx. 50 years) to protect bone and heart health.

Q: The rise in FSH during menopause is primarily attributed to which of the following physiological changes?

Decreased ovarian inhibin secretion. **Explanation:** The hallmark of the menopausal transition is a significant rise in **Follicle Stimulating Hormone (FSH)**. This occurs primarily due to the depletion of the ovarian follicle pool. **Why Option B is Correct:** In a functioning ovary, **Inhibin B** (secreted by granulosa cells of antral follicles) provides a potent negative feedback signal specifically to the anterior pituitary to suppress FSH secretion. As the number of follicles declines during perimenopause and menopause, **Inhibin B levels drop first**, even before estradiol levels significantly fall. This loss of negative feedback is the earliest and most significant trigger for the rise in FSH. **Analysis of Incorrect Options:** * **Option A:** While estradiol levels eventually fall, **Inhibin B is the primary regulator of FSH**. Estradiol provides feedback to both the hypothalamus and pituitary, but its decline usually occurs later in the transition compared to the drop in Inhibin. * **Option B:** In menopause, GnRH frequency and amplitude actually **increase** (not decrease) due to the lack of negative feedback from ovarian steroids. * **Option D:** **Anti-Müllerian Hormone (AMH)** levels **decrease** (not increase) as the primordial follicle pool is exhausted. AMH is currently considered the most sensitive marker for ovarian reserve. **High-Yield Clinical Pearls for NEET-PG:** * **Earliest biochemical marker** of ovarian aging: Decreased **Inhibin B**. * **Best marker for ovarian reserve**: **AMH** (levels are cycle-independent). * **Diagnostic FSH level for menopause**: **>40 IU/L** (though >25-30 IU/L is often seen in the transition). * The **LH/FSH ratio** reverses in menopause (FSH > LH) because FSH has a slower clearance rate from the circulation.

Q: In a postmenopausal woman, estrogen therapy is initiated. The risk of which of the following conditions will not be increased?

Osteoporosis. **Explanation:** The correct answer is **B. Osteoporosis**. Estrogen plays a critical role in maintaining bone mineral density (BMD) by inhibiting osteoclast activity and promoting osteoblast survival. In postmenopausal women, the decline in estrogen leads to accelerated bone resorption. Therefore, initiating Estrogen Replacement Therapy (ERT) is actually **protective** against osteoporosis and reduces the risk of fractures. It is a primary indication for Hormone Replacement Therapy (HRT), not a risk. **Analysis of Incorrect Options:** * **Gallstones (A):** Estrogen increases the saturation of cholesterol in bile and decreases gallbladder motility, leading to an increased risk of cholelithiasis (gallstones). * **Endometrial Carcinoma (C):** Unopposed estrogen causes endometrial hyperplasia. In women with an intact uterus, estrogen therapy significantly increases the risk of endometrial cancer. This is why progesterone is always added (Combined HRT) for women who have not undergone a hysterectomy. * **Breast Cancer (D):** Long-term use of combined HRT (Estrogen + Progesterone) is associated with a slightly increased risk of breast cancer, as estrogen stimulates the proliferation of mammary epithelial cells. **NEET-PG High-Yield Pearls:** 1. **Indication:** The most common indication for HRT is the management of moderate-to-severe vasomotor symptoms (hot flashes). 2. **Uterine Status:** If the uterus is present, use **Combined HRT** (E+P). If the patient has had a hysterectomy, use **ERT** (Estrogen only). 3. **Lipid Profile:** Oral estrogen increases HDL and decreases LDL (cardioprotective effect on lipids) but increases triglycerides. 4. **Contraindications:** Undiagnosed vaginal bleeding, active thromboembolism (DVT/PE), and estrogen-dependent tumors (Breast/Endometrial CA).

Q: Levels of which of the following hormones are increased in post-menopausal women?

FSH. **Explanation:** The primary physiological hallmark of menopause is the depletion of ovarian follicles. As the number of follicles declines, there is a significant decrease in the production of **Estrogen** (specifically estradiol) and **Inhibin B**. Under normal physiological conditions, Estrogen and Inhibin exert negative feedback on the anterior pituitary and hypothalamus. When these levels drop during menopause, the negative feedback loop is lost. Consequently, the pituitary gland increases the secretion of **Follicle-Stimulating Hormone (FSH)** and Luteinizing Hormone (LH) in an attempt to stimulate the non-responsive ovaries. FSH levels rise more significantly and earlier than LH, making it the most sensitive biochemical marker for menopause. **Analysis of Options:** * **A. Estrogen:** Levels decrease significantly because the ovaries no longer produce functional follicles. * **C. Progesterone:** Levels decrease because ovulation ceases, meaning no corpus luteum is formed to produce progesterone. * **D. Cortisol:** This is an adrenal hormone. While aging affects the endocrine system, cortisol levels do not characteristically increase as a direct result of menopause. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnostic Threshold:** An FSH level **>40 mIU/mL** is generally considered diagnostic of menopause in the clinical context of amenorrhea. * **Predominant Estrogen:** In post-menopausal women, **Estrone (E1)** becomes the dominant estrogen (produced via peripheral conversion of androstenedione in adipose tissue), replacing Estradiol (E2). * **LH/FSH Ratio:** In menopause, the FSH level is typically higher than the LH level (FSH > LH). * **First Sign:** The earliest biochemical change in the perimenopausal period is a decrease in **Inhibin B**, leading to a subtle rise in FSH.

Q: What is the major source of estrogen in postmenopausal women?

Peripheral conversion of androstenedione. **Explanation:** In postmenopausal women, the ovaries cease follicular activity, leading to a significant drop in estradiol levels. The primary source of estrogen shifts from direct ovarian secretion to the **peripheral conversion of androgens.** **1. Why Option A is correct:** The major circulating estrogen in menopause is **Estrone (E1)**, which is weaker than the reproductive-age estradiol (E2). This estrone is produced via the aromatization of **androstenedione** (secreted primarily by the adrenal glands and some by the ovarian stroma). This conversion occurs in peripheral tissues, predominantly in **adipose tissue** (fat), through the enzyme aromatase. **2. Why the other options are incorrect:** * **Option B:** While the adrenal glands secrete the *precursors* (androstenedione and DHEA), they do not secrete significant amounts of active estrogen directly. * **Option C:** Although the postmenopausal ovary continues to secrete small amounts of testosterone due to LH stimulation of the stroma, this is not the primary source of systemic estrogen. Testosterone is more commonly converted to estradiol, whereas androstenedione is the primary precursor for estrone. **High-Yield Clinical Pearls for NEET-PG:** * **Estrogen Potency:** Estradiol (E2) > Estrone (E1) > Estriol (E3). * **Dominant Estrogen:** In pregnancy, it is **Estriol (E3)**; in menopause, it is **Estrone (E1)**. * **Obesity Link:** Obese postmenopausal women have higher estrone levels due to increased peripheral aromatization in adipose tissue, placing them at a higher risk for **endometrial hyperplasia and carcinoma.** * **Hormonal Profile:** Menopause is characterized by Low Estrogen, Low Inhibin, and **High FSH** (FSH >40 IU/L is diagnostic). FSH rises more significantly than LH.

Question 1

Which of the following is NOT a long-term benefit of hormone replacement therapy?

Accepted Answer

Increased duration of menstrual cycles

Answer

Decreased rate of colorectal cancer

Answer

Decreased rate of fracture

Answer

Increased bone mineral density

Question 2

A 58-year-old postmenopausal woman on estrogen replacement therapy complains of recent onset of spotting. A bimanual pelvic examination is unremarkable. What is the most likely diagnosis?

Accepted Answer

Endometrial hyperplasia

Answer

Cervical carcinoma

Answer

Cervical polyp

Answer

Dysfunctional uterine bleeding

Question 3

Postmenopausal hormone replacement therapy decreases the incidence of which malignancy?

Accepted Answer

Colorectal

Answer

Breast

Answer

Ovarian

Answer

Endometrial

Question 4

Hormone therapy in postmenopausal women is indicated for treatment of all the following conditions EXCEPT:

Accepted Answer

Cardiovascular disease

Answer

Vasomotor symptoms

Answer

Osteoporosis

Answer

Vaginal atrophy

Question 5

The rise in FSH during menopause is primarily attributed to which of the following physiological changes?

Accepted Answer

Decreased ovarian inhibin secretion

Answer

Diminished estradiol feedback

Answer

Decreased GnRH frequency

Answer

Increased AMH concentration

Question 6

In a postmenopausal woman, estrogen therapy is initiated. The risk of which of the following conditions will not be increased?

Accepted Answer

Osteoporosis

Answer

Gallstones

Answer

Endometrial carcinoma

Answer

Breast cancer

Question 7

Which of the following is NOT a benefit of hormone replacement therapy?

Accepted Answer

Prevents breast cancer

Answer

Prevents osteoporosis

Answer

Prevents colon cancer

Answer

Prevents stroke

Question 8

Which of the following is true about hormonal changes during menopause?

Accepted Answer

Gonadotropins and estrogens

Answer

LH/TSH

Answer

Estrogens and Gonadotropins

Answer

Estrogens and Gonadotropins

Question 9

Levels of which of the following hormones are increased in post-menopausal women?

Accepted Answer

FSH

Answer

Estrogen

Answer

Progesterone

Answer

Cortisol

Question 10

What is the major source of estrogen in postmenopausal women?

Accepted Answer

Peripheral conversion of androstenedione

Answer

Secretion from the adrenals

Answer

Ovarian secretion of testosterone

Answer

None of the above

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?